Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][5] - The company has developed its first novel payload, PH1, which is a spliceosome modulator designed to disrupt RNA splicing within cells, differentiating it from current ADC payloads [5] Product Pipeline - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [5] - Preclinical studies have shown that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs [5] - The company is generating validating data on its novel payload PH1 to advance its lead asset and other undisclosed targets [5] Upcoming Events - Akari Therapeutics will participate in the Virtual Investor Closing Bell Series on September 4, 2025, where the CEO will provide a corporate overview and discuss the innovative payload platform [3][4] - Investors will have the opportunity to submit questions live during the event [3]